Compare HP & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | RLAY |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.8B |
| IPO Year | 1994 | 2020 |
| Metric | HP | RLAY |
|---|---|---|
| Price | $31.37 | $17.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $34.17 | $19.50 |
| AVG Volume (30 Days) | 1.2M | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,746,013,000.00 | $15,355,000.00 |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $3.34 | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 35.89 | ★ 53.44 |
| 52 Week Low | $15.17 | $3.03 |
| 52 Week High | $41.82 | $19.93 |
| Indicator | HP | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 30.46 | 62.21 |
| Support Level | $25.05 | $6.67 |
| Resistance Level | $36.65 | N/A |
| Average True Range (ATR) | 1.40 | 1.01 |
| MACD | -0.50 | 0.26 |
| Stochastic Oscillator | 0.17 | 69.21 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.